MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective June 28, 2018, the Board of Directors of Mount Tam Biotechnologies, Inc., a Nevada corporation (the “Company”), voted to increase the size of the Board from four directors to five directors and to appoint James Farrell to the Board to fill the resulting vacancy. Mr. Farrell accepted the appointment and joined the Board of Directors effective June 28, 2018.
Biographical Information
Mr. Farrell is a successful strategist, innovator, entrepreneur and investor across a number of fields from bio-pharma to medical equipment to groundbreaking food and energy innovations. He graduated from Cornell University with Bachelor’s and Masters degrees in Bio-Agricultural Engineer (B.S. and M.Eng.), and also received a Masters of Business Administration (MBA) from Harvard. Mr. Farrell worked for several years at McKinsey & Company as a Senior Engagement Manager focused on Strategy Development and Implementation. He has owned and participated in multiple businesses from inception through company sale, with first-hand experience in all company stages from start-up to rapid growth to positioning for and executing liquidity events. Mr. Farrell has been retired since June 2013 and, since that time, has been actively managing his various business investments.
The Board of Directors appointed Mr. Farrell to the Board based, in part, on his team-building experience, his strong strategic perspective, and his focus on the excellence in execution required to accelerate an enterprise forward.
Mr. Farrell is the manager of Climate Change Investigation, Innovation and Investment, LLC (“CC3I”), which as of the date of this Report owned approximately 15% of the Company’s outstanding common stock. There is no agreement between the Company and CC3I relating to an appointment of Mr. Farrell as a Director of the Company.
As of the date of this Report, the Company did not have separate standing audit, nominating, or compensation committees, and Mr. Farrell was not appointed to any committees in connection with his appointment.
As of the date of this Report, other than the ownership of the Company’s common stock by CC3I as noted above, there were no transactions between the Company and Mr. Farrell or any entity controlled by him.
Item 7.01 Regulation FD Disclosure.
On June 28, 2018, the Company issued a press release regarding the appointment of Mr. Farrell to the Board of Directors, which is attached hereto as Exhibit 99.1.
The press release included as Exhibit 99.1 will be deemed to be “furnished” rather than “filed,” to the rules of the Securities and Exchange Commission
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated June 28, 2018 |
Mount TAM Biotechnologies, Inc. ExhibitEX-99.1 2 mntm_ex99z1.htm EXHIBIT 99.1 Mount Tam Biotechnologies Announces Appointment of New Member to the Board of Directors NOVATO,…To view the full exhibit click here
About MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM)
Mount Tam Biotechnologies, Inc., formerly TabacaleraYsidron, Inc., is a specialty biopharmaceutical company established to develop and bring to market a portfolio of pharmaceutical products targeting the treatment of autoimmune diseases. The Company is focused on the development of product candidate in the field of systemic lupus erythematosus (SLE), an orphan autoimmune disease. The Company’s product candidate, TAM-01, is a rapamycin analog, which exerts its action through direct binding and inhibition of the mammalian Target of Rapamycin (mTOR). mTOR is a key regulatory pathway, which is altered in individuals suffering from autoimmune disorders, including lupus. The Company’s product candidate, TAM-01, is a small-molecule inhibitor of mTOR. TAM-01 has completed preliminary toxicology, safety, pharmacokinetics (PK), absorption, distribution, metabolism and excretion (ADME), and preliminary scale up manufacturing studies.